1. Scrip
  2. >>Business
  3. >>Deals

Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer

 
• By Jessica Merrill

The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.

tumor microenvironment
Gilead signed a deal with Compugen for an early novel immuno-oncology asset • Source: Shutterstock

Gilead Sciences, Inc. has partnered with Compugen Ltd. on the development and commercialization of a preclinical asset that could be a new kind of cancer immunotherapy. Gilead agreed to pay $60m up front for rights to Compugen’s COM503, which is a potential first-in-class antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment to inhibit cancer growth.

Key Takeaways
  • Gilead agreed to pay $60m up front for rights to Compugen’s COM503 for solid tumors.

The companies announced the collaboration on 19 December, under which Gilead will pay $60m up front and another $30m in...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Deals

J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout

 
• By Andrew McConaghie

Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.

Gilead Teams Up With Sweden’s Sprint For Latest Oncology Pact

 
• By Kevin Grogan

Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.

Biogen Joins The Macrocycle Melee With Dayra Tie-Up

 
• By Alaric DeArment

Deal Snapshot: The biotech is joining forces with the Versant Ventures-backed startup, paying $50m upfront to apply its macrocycle peptide platform to immunological diseases.

More from Business

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.